[1] Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50（1）:204-210.
[2] De Alwis NM,Day CP. Non-alcoholic fatty liver disease:The mist gradually clears. J Hepatol,2008.48（Suppl 1）:S104-S112.
[3] Day CP,James OF. Steatohepatitis:a tale of two“hits”? Gastroenterology,1998,114（4）:842-845.
[4] Vanni E,Bugianesi E. The gut-liver axis in nonalcoholic fatty liver disease:Another pathway to insulin resistance?Hepatology,2009,49（6）:1790-1792.
[5] Gao B,Jeong WI,Tian Z. Liver:An organ with predominant innate immunity. Hepatology,2008,47（2）:729-736.
[6] Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses. Can J Physiol Pharmacol,1998,76（5）:479-484.
[7] DiBaise JK,Zhang H,Crowell MD,et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc,2008,83（4）:460-469.
[8] Carter BA,Karpen SJ. Intestinal failure-associated liver disease:management and treatment strategies past,present,and future. Semin Liver Dis,2007,27:251-258.
[9] Gabele E,Dostert K,Hofmann C,et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55（6）:1391-1399.
[10] Henao-Mejia J,Elinav E,Jin C,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature,2012,482（7384）:179-185.
[11] Abu-Shanab A,Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol,2010,7（12）:691-701.
[12] Rao RK. Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol,2008,447:171-183.
[13] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49（6）:1877-1887.
[14] Seki E,Schnabl B. Role of innate immunity and the microbiota in liver fibrosis:crosstalk between the liver and gut. J Physiol,2012.590（Pt 3）:447-458.
[15] Seki E,Brenner DA. Toll-like receptors and adaptor molecules in liver disease:Update. Hepatology,2008,48（1）:322-335.
[16] Alisi A,Carsetti R,Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology,2011,54（5）:1500-1502.
[17] Miura K,Seki E,Ohnishi H,et al. Role of Toll-like receptors and their downstream molecules in the development of non-alcoholic fatty liver disease. Gastroenterol Res Pract,2010,2010:3628-3647.
[18] Kawai T,Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors. Nat Immunol,2010,11（5）:373-384.
[19] Rivera CA,Adegboyega P,van Rooijen N,et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol,2007,47（4）:571-579.
[20] Li L,Chen L,Hu L,et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology,2011,54（5）:1620-1630.
[21] Miura K,Kodama Y,Inokuchi S,et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology,2010,139（1）:323-334
[22] Blasius AL,Beutler B. Intracellular Toll-like receptors. Immunity,2010,32（3）:305-315.
[23] Gao B. Innate immunity and steatohepatitis:a critical role of another toll （TLR-9）. Gastroenterology,2010.139（1）:27-30.
[24] Cani PD,Bibiloni R,Knauf C,et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes,2008,57（6）:1470-1481.
[25] Membrez M,Blancher F,Jaquet M,et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. Faseb J,2008,22（7）:2416-2426.
[26] Fan J,Xu Z,Wang G. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol, 2005,11（32）:5053.
[27] Cani PD,Neyrinck AM,Fava F,et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia,2007,50（11）:2374-2383.
[28] Li Z,Yang S,Lin H,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology,2003,37（2）:343-350.
[29] Ma X,Hua J,Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol,2008,49（5）:821-830.
[30] Xu RY,Wan YP,Fang QY,et al. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr,2012,50（1）:72-77. |
